Becton Dickinson and Company (BDX) : Tuesdays money flow analysis of Becton Dickinson and Company (BDX) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $21.17 million. In comparison, the inflow of money on upticks was a meager $18.72 million. The dollar value of composite uptick trades minus the downtick trades was negative $2.45 million. The uptick to downtick ratio of 0.88 in the money flow shows weakness. The downtick transaction value was high at $5.95 million, which denotes distribution on strength.. Hence, the net money flow in the stock was negative ($5.95 million). Becton Dickinson and Company (BDX) gained $0.31 at $177.56, a change of 0.17% over the previous days close.
Also, In the latest statement by the brokerage house, UBS maintains its outlook on Becton Dickinson and Company (NYSE:BDX). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $182 per share to $195 per share. The rating by the firm was issued on August 5, 2016.
Shares of Becton, Dickinson and Company rose by 1.61% in the last five trading days and 0.54% for the last 4 weeks. Becton, Dickinson and Company is up 6.81% in the last 3-month period. Year-to-Date the stock performance stands at 16.31%.
Becton Dickinson and Company (NYSE:BDX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $176.76 and $176.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $178.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $177.73, notching a gain of 0.27% for the day. The total traded volume was 747,316 . The stock had closed at $177.25 on the previous day.
In a related news,The officer (Executive Vice President) of Becton Dickinson & Co, Cohen Gary M sold 29,367 shares at $176.81 on August 11, 2016. The Insider selling transaction had a total value worth of $5,192,379. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.